Unexplained deaths spark FDA probe of Lilly's Zyprexa Relprevv
This article was originally published in Scrip
Executive Summary
US regulators on 18 June said they were investigating two "unexplained" cases in which patients died 3-4 days after receiving an intramuscular injection of Lilly's tightly controlled antipsychotic Zyprexa Relprevv (olanzapine pamoate), which is only permitted to be administered in the US at specially certified health care facilities.